| Christopher Drew, MD | |
|
842 W South Boulder Rd, #202, Louisville, CO 80027-2413 | |
| (303) 665-5155 | |
| Not Available |
| Full Name | Christopher Drew |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Psychiatry |
| Location | 842 W South Boulder Rd, Louisville, Colorado |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821136755 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 43526 (Colorado) | Primary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | A62672 (California) | Secondary |
| Entity Name | Jefferson Center For Mental Health |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154403798 PECOS PAC ID: 9032018882 Enrollment ID: O20031231000357 |
News Archive
CEL-SCI Corporation. (NYSE Amex: CVM), a biotechnology company entering a late stage oncology trial and focused on infectious disease, today announced that it has entered into a definitive agreement with several institutional investors to sell 9.7 million units, with each unit consisting of one of the Company's common shares and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $4.4 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.
Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous administration of VELCADE (bortezomib) in patients with relapsed multiple myeloma. These data were presented at the 52nd annual meeting of the American Society of Hematology, held December 4-7 in Orlando, Florida.
As children are hard at work learning at school, viruses and bacteria are also hard at work, spreading from one child to another. One of the most contagious ailments is pink eye. Though not life-threatening the sticky infection is a hassle for parents, teachers and students.
Rhesus monkeys were completely protected from the deadly Ebola virus when treated three days after infection with a compound that blocks the virus's ability to replicate. These encouraging preclinical results suggest the compound, known as GS-5734, should be further developed as a potential treatment, according to research findings to be presented tomorrow at the IDWeek conference.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Drew, MD 300 Center Dr, Suite G-374, Superior, CO 80027-8625 Ph: (303) 665-5155 | Christopher Drew, MD 842 W South Boulder Rd, #202, Louisville, CO 80027-2413 Ph: (303) 665-5155 |
News Archive
CEL-SCI Corporation. (NYSE Amex: CVM), a biotechnology company entering a late stage oncology trial and focused on infectious disease, today announced that it has entered into a definitive agreement with several institutional investors to sell 9.7 million units, with each unit consisting of one of the Company's common shares and 0.50 warrants to purchase one share of common stock, for gross proceeds of approximately $4.4 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering.
Millennium: The Takeda Oncology Company today reported results from a randomized, international Phase III clinical trial comparing subcutaneous and intravenous administration of VELCADE (bortezomib) in patients with relapsed multiple myeloma. These data were presented at the 52nd annual meeting of the American Society of Hematology, held December 4-7 in Orlando, Florida.
As children are hard at work learning at school, viruses and bacteria are also hard at work, spreading from one child to another. One of the most contagious ailments is pink eye. Though not life-threatening the sticky infection is a hassle for parents, teachers and students.
Rhesus monkeys were completely protected from the deadly Ebola virus when treated three days after infection with a compound that blocks the virus's ability to replicate. These encouraging preclinical results suggest the compound, known as GS-5734, should be further developed as a potential treatment, according to research findings to be presented tomorrow at the IDWeek conference.
› Verified 2 days ago
Dr. David Ethan Miller, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 400 S Mccaslin Blvd Ste 110, Louisville, CO 80027 Phone: 720-279-9682 Fax: 720-279-9687 | |
Alicia Erin Bennett, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 100 Health Park Drive, Louisville, CO 80027 Phone: 303-673-1000 Fax: 303-306-7753 | |
Dr. Brian Alexander Anderson, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2255 S 88th St, Louisville, CO 80027 Phone: 303-666-2095 Fax: 303-666-1801 | |
Dr. Allison Rachel Gray, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 275 Century Cir Ste 100, Louisville, CO 80027 Phone: 720-738-8738 Fax: 720-862-2184 | |
Dr. Roderick Shields O'brien, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2255 S 88th St, Louisville, CO 80027 Phone: 303-673-9990 | |
Dr. Marcy Cooper, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1314 Main St Unit 204, Louisville, CO 80027 Phone: 303-666-0443 Fax: 303-666-7505 | |
Dr. Kytja K.s. Voeller, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 363 Centennial Pkwy Ste 110, Louisville, CO 80027 Phone: 303-442-4750 Fax: 303-443-4682 |